cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3535/kds-5vt-gba
title: Maianthemum F.H.Wigg.

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/xkv-w2s-evp
title: Muntiacus muntjak (Zimmermann, 1780)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/4xt-fbe-7qf
title: Bubalus C. H. Smith, 1827

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/pff-yal-qar
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/7t2-cdk-g2q
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/wy7-zsr-f4w
title: Muntiacus muntjak (Zimmermann, 1780)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/c08-jwj-bxh
title: Orthiopteris Copel.

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/sm6-xk7-ved
title: Rhinoceros Linnaeus, 1758

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/vyq-0wv-q8l
title: Voacanga Thouars

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/3xc-3qg-gqs
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/6k2-8kh-6wa
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/yxj-axj-qqf
title: Capricornis sumatraensis (Bechstein, 1799)

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/40w-3tk-q4v
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/k7h-qm7-74t
title: Magnoliopsida

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/41g-3zd-tkt
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/9eb-m52-dmc
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/4vx-cva-26k
title: Rusa C. H. Smith, 1827

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/p1z-mkj-85a
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/tbe-tlj-dlj
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/5gz-0x5-hjv
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/epw-pen-sfe
title: †Anthracosia W. King, 1856

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/f2g-xt3-e6e
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/k5r-g1p-581
title: Zelkova Spach

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.3535/pbl-r01-cvg
title: Plantae

description: Digital Specimen for the physical specimen hosted at Naturalis Biodiversity Center.
DOI: 10.17632/42p3sxt73r
title: Jasmine Flowers (Jasminum sambac (L.) Ait.) Color Degradation Kinetics Modeling Dataset

description: This dataset contains time-series image data used in the study “Jasmine Flowers Color Degradation User-Coded Computer Vision Image Analysis Tool and Kinetics Modeling” submitted to AgriEngineering. From the images of jasmine flowers over 25 h of natural storage, the RGB values were derived utilizing ImageJ, and 12 color indices were evaluated for color degradation kinetics modeling. The dataset consists of time-series inputs used to characterize the selected kinetic modeling (Zeroth, First Order, Exponential, Page, and Peleg) of color degradation of jasmine petals and pedicels during natural dehydration under storage. 
Sheet 1 of the file contains the RGB values of 4 samples for 25 h data for petals of jasmine flower
Sheet 2 of the file contains the RGB values of 4 samples for 25 h data for pedicles of jasmine flower
Sheet 3 of the file contains the consolidated data of RGB values and color indices used with color kinetic analysis.
DOI: 10.17632/42p3sxt73r.1
title: Jasmine Flowers (Jasminum sambac (L.) Ait.) Color Degradation Kinetics Modeling Dataset

description: This dataset contains time-series image data used in the study “Jasmine Flowers Color Degradation User-Coded Computer Vision Image Analysis Tool and Kinetics Modeling” submitted to AgriEngineering. From the images of jasmine flowers over 25 h of natural storage, the RGB values were derived utilizing ImageJ, and 12 color indices were evaluated for color degradation kinetics modeling. The dataset consists of time-series inputs used to characterize the selected kinetic modeling (Zeroth, First Order, Exponential, Page, and Peleg) of color degradation of jasmine petals and pedicels during natural dehydration under storage. 
Sheet 1 of the file contains the RGB values of 4 samples for 25 h data for petals of jasmine flower
Sheet 2 of the file contains the RGB values of 4 samples for 25 h data for pedicles of jasmine flower
Sheet 3 of the file contains the consolidated data of RGB values and color indices used with color kinetic analysis.
DOI: 10.17632/r8htzstd6b.1
title: EKGuniversit201

description: This dataset contains information from 201 university students about their health status
DOI: 10.6084/m9.figshare.28920459
title: CircMYO9A inhibits influenza A virus replication by dampening haemagglutinin cleavage via increasing SERPINE1/PAI-1 expression

description: Circular RNAs (circRNAs) represent a class of widespread and diverse covalently closed circular endogenous RNAs that play critical roles in regulating gene expression in mammals. However, the roles and regulatory mechanisms of circRNAs during influenza A virus (IAV) infection remain largely unexplored. In this study, we screened the circRNA transcription profiles of WSN-infected cells to identify circRNAs involved in viral replication and identified a novel differentially expressed circular RNA, circMYO9A. Mechanistically, circMYO9A acts as a competing endogenous RNA (ceRNA) for SERPINE1/PAI-1 by sponging miR-6059-3p, thereby increasing SERPINE1/PAI-1 expression, which restricts IAV haemagglutinin cleavage and subsequently reduces the infectivity of progeny viruses. Importantly, our findings demonstrate that circMYO9A significantly inhibits viral replication in the lungs of infected mice, potentially increasing their survival during IAV infection. These results demonstrate that circRNAs play crucial roles in inhibiting IAV replication and provide novel insights into potential therapeutic strategies involving circRNAs.
DOI: 10.6084/m9.figshare.28920459.v1
title: CircMYO9A inhibits influenza A virus replication by dampening hemagglutinin cleavage via increasing SERPINE1/PAI-1 expression

description: Circular RNAs (circRNAs) represent a class of widespread and diverse covalently closed circular endogenous RNAs that play critical roles in regulating gene expression in mammals. However, the roles and regulatory mechanisms of circRNAs during influenza A virus (IAV) infection remain largely unexplored. In this study, we screened the circRNA transcription profiles of WSN-infected cells to identify circRNAs involved in viral replication and identified a novel differentially expressed circular RNA, circMYO9A. Mechanistically, circMYO9A acts as a competing endogenous RNA (ceRNA) for SERPINE1/PAI-1 by sponging miR-6059-3p, thereby increasing SERPINE1/PAI-1 expression, which restricts IAV hemagglutinin cleavage and subsequently reduces the infectivity of progeny viruses. Importantly, our findings demonstrate that circMYO9A significantly inhibits viral replication in the lungs of infected mice, potentially increasing their survival during IAV infection. These results demonstrate that circRNAs play crucial roles in inhibiting IAV replication and provide novel insights into potential therapeutic strategies involving circRNAs.
DOI: 10.6084/m9.figshare.29040690
title: Gene-modified genotype II live attenuated African swine fever virus induces cross-protection against genotype I but not against genotype IX

description: African swine fever virus originated in a wildlife cycle in East Africa and spread to domestic pigs. At least twenty-three genotypes are present in Africa whereas only genotypes I and II have spread to other continents. Vaccine development has been directed mainly to genotype II. The ability of genotype II vaccines to induce cross-protection against other genotypes is unknown. Here, we compared cross-protection induced in pigs by an attenuated multiple gene-deleted genotype II modified live vaccine candidate against challenge with different genotypes. Protection against homologous virulent genotype II virus was 100%. Cross-protection against virulent genotype I virus varied between 57 and 71%. However, no protection was achieved against genotype IX challenge. The results indicate potential for use of vaccines in regions where genotypes I and II are circulating.
DOI: 10.6084/m9.figshare.29040690.v1
title: Gene-modified genotype II live attenuated African swine fever virus induces cross-protection against genotype I but not against genotype IX

description: African swine fever virus originated in a wildlife cycle in East Africa and spread to domestic pigs. At least twenty-three genotypes are present in Africa whereas only genotypes I and II have spread to other continents. Vaccine development has been directed mainly to genotype II. The ability of genotype II vaccines to induce cross-protection against other genotypes is unknown. Here, we compared cross-protection induced in pigs by an attenuated multiple gene-deleted genotype II modified live vaccine candidate against challenge with different genotypes. Protection against homologous virulent genotype II virus was 100%. Cross-protection against virulent genotype I virus varied between 57 and 71%. However, no protection was achieved against genotype IX challenge. The results indicate potential for use of vaccines in regions where genotypes I and II are circulating.
DOI: 10.6084/m9.figshare.28174827
title: Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis

description: Although the efficacy of mepolizumab in reducing exacerbations and oral corticosteroid (OCS) use in severe asthma is well-established, real-world long-term effectiveness data are limited. This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period. This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial and Medicare Databases. Outcomes included asthma exacerbations, OCS use, and exacerbation-related healthcare resource utilization (HCRU) and costs, assessed 12-months pre-index (baseline) and annually during the 4-year follow-up period. Among 189 eligible patients, mean asthma exacerbation rate (AER) declined progressively from baseline during follow-up: AER decreased by 53.8% at Year 1 and 73.8% by Year 4 (<i>p</i> &lt; 0.001). The annual OCS prescription rate reduced from baseline by 41.1% at Year 1 and 62.2% at Year 4 (<i>p</i> &lt; 0.001). The proportion of patients with both no exacerbations and no OCS use progressively increased from 6.4% at baseline to 18.5% at Year 1 and 41.8% at Year 4. Exacerbation-related HCRU including inpatient, emergency room, and outpatient office visits decreased from baseline (9.0%, 21.7%, and 78.8%, respectively), at Year 1 (3.2%, 12.2%, and 49.2%), and Year 4 (0.0%, 4.8%, and 31.8%). Exacerbation-related healthcare costs declined from $4,635 at baseline to $1,487 at Year 1 and $217 at Year 4 (<i>p</i> &lt; 0.001). Patients treated with mepolizumab demonstrated progressive and sustained long-term, real-world reductions in exacerbation frequency, OCS dependency, and exacerbation-related HCRU and costs over 4 years.
DOI: 10.6084/m9.figshare.28174827.v2
title: Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis

description: Although the efficacy of mepolizumab in reducing exacerbations and oral corticosteroid (OCS) use in severe asthma is well-established, real-world long-term effectiveness data are limited. This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period. This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial and Medicare Databases. Outcomes included asthma exacerbations, OCS use, and exacerbation-related healthcare resource utilization (HCRU) and costs, assessed 12-months pre-index (baseline) and annually during the 4-year follow-up period. Among 189 eligible patients, mean asthma exacerbation rate (AER) declined progressively from baseline during follow-up: AER decreased by 53.8% at Year 1 and 73.8% by Year 4 (<i>p</i> &lt; 0.001). The annual OCS prescription rate reduced from baseline by 41.1% at Year 1 and 62.2% at Year 4 (<i>p</i> &lt; 0.001). The proportion of patients with both no exacerbations and no OCS use progressively increased from 6.4% at baseline to 18.5% at Year 1 and 41.8% at Year 4. Exacerbation-related HCRU including inpatient, emergency room, and outpatient office visits decreased from baseline (9.0%, 21.7%, and 78.8%, respectively), at Year 1 (3.2%, 12.2%, and 49.2%), and Year 4 (0.0%, 4.8%, and 31.8%). Exacerbation-related healthcare costs declined from $4,635 at baseline to $1,487 at Year 1 and $217 at Year 4 (<i>p</i> &lt; 0.001). Patients treated with mepolizumab demonstrated progressive and sustained long-term, real-world reductions in exacerbation frequency, OCS dependency, and exacerbation-related HCRU and costs over 4 years.
DOI: 10.6084/m9.figshare.25641142
title: Prevalence and predictors of medication adherence among adolescents and adults with asthma in Ethiopia: a systematic review and meta-analysis

description: This review aimed to estimate the pooled prevalence and predictors of medication adherence among adolescents and adults with asthma in Ethiopia. Primary studies were searched from PubMed, Scopus, HINARI, and Google Scholar from January 1, 2010 to December 10, 2023. In addition, we have used citation tracking. Observational studies (cross sectional, case control, and cohort) conducted among asthmatic patients ≥15 years old in Ethiopia, published in English language were included. After screening, the studies were assessed using Joanna Briggs Institute (JBI) critical appraisal tool and data were extracted using a checklist. Heterogeneity was assessed using forest plot, Q-statistics and <i>I</i><sup>2</sup>. The review was performed among 13 institution-based studies with a total of 2901 participants with asthma. About 1058 participants had comorbid disease and 354 were cigarette smokers. The pooled prevalence of adherence to medications among patients with asthma was 40.50% (95% CI: 28.05, 52.96; <i>p</i> value <i>&lt;</i> 0.001) with high heterogeneity (<i>I</i><sup>2</sup> = 98.25%, <i>p</i> &lt; 0.001). Getting health education about asthma and having comorbid disease were predictors of medication adherence among adolescents and adults with asthma in Ethiopia. The pooled prevalence of medication adherence among adolescents and adults with asthma in Ethiopia is low and indicated that three out of five adolescents and adults with asthma were non-adherent to medications. This implies the Ministry of Health should develop different strategies to improve medication adherence including patient education and strengthening the health care system. Multicenter longitudinal studies should be further conducted by using objective methods of adherence measurement and large sample size.
DOI: 10.6084/m9.figshare.25641142.v1
title: Prevalence and predictors of medication adherence among adolescents and adults with asthma in Ethiopia: a systematic review and meta-analysis

description: This review aimed to estimate the pooled prevalence and predictors of medication adherence among adolescents and adults with asthma in Ethiopia. Primary studies were searched from PubMed, Scopus, HINARI, and Google Scholar from January 1, 2010 to December 10, 2023. In addition, we have used citation tracking. Observational studies (cross sectional, case control, and cohort) conducted among asthmatic patients ≥15 years old in Ethiopia, published in English language were included. After screening, the studies were assessed using Joanna Briggs Institute (JBI) critical appraisal tool and data were extracted using a checklist. Heterogeneity was assessed using forest plot, Q-statistics and <i>I</i><sup>2</sup>. The review was performed among 13 institution-based studies with a total of 2901 participants with asthma. About 1058 participants had comorbid disease and 354 were cigarette smokers. The pooled prevalence of adherence to medications among patients with asthma was 40.50% (95% CI: 28.05, 52.96; <i>p</i> value <i>&lt;</i> 0.001) with high heterogeneity (<i>I</i><sup>2</sup> = 98.25%, <i>p</i> &lt; 0.001). Getting health education about asthma and having comorbid disease were predictors of medication adherence among adolescents and adults with asthma in Ethiopia. The pooled prevalence of medication adherence among adolescents and adults with asthma in Ethiopia is low and indicated that three out of five adolescents and adults with asthma were non-adherent to medications. This implies the Ministry of Health should develop different strategies to improve medication adherence including patient education and strengthening the health care system. Multicenter longitudinal studies should be further conducted by using objective methods of adherence measurement and large sample size.
DOI: 10.6084/m9.figshare.28174827.v1
title: Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis

description: Although the efficacy of mepolizumab in reducing exacerbations and oral corticosteroid (OCS) use in severe asthma is well-established, real-world long-term effectiveness data are limited. This study evaluated the real-world impact of mepolizumab treatment in patients with severe asthma over a 4-year follow-up period. This was a retrospective cohort study of patients with asthma initiating mepolizumab (index date: first claim, November 2015–September 2019) using the Merative MarketScan Commercial and Medicare Databases. Outcomes included asthma exacerbations, OCS use, and exacerbation-related healthcare resource utilization (HCRU) and costs, assessed 12-months pre-index (baseline) and annually during the 4-year follow-up period. Among 189 eligible patients, mean asthma exacerbation rate (AER) declined progressively from baseline during follow-up: AER decreased by 53.8% at Year 1 and 73.8% by Year 4 (p &lt; 0.001). The annual OCS prescription rate reduced from baseline by 41.1% at Year 1 and 62.2% at Year 4 (p &lt; 0.001). The proportion of patients with both no exacerbations and no OCS use progressively increased from 6.4% at baseline to 18.5% at Year 1 and 41.8% at Year 4. Exacerbation-related HCRU including inpatient, emergency room, and outpatient office visits decreased from baseline (9.0%, 21.7%, and 78.8%, respectively), at Year 1 (3.2%, 12.2%, and 49.2%), and Year 4 (0.0%, 4.8%, and 31.8%). Exacerbation-related healthcare costs declined from $4,635 at baseline to $1,487 at Year 1 and $217 at Year 4 (p &lt; 0.001). Patients treated with mepolizumab demonstrated progressive and sustained long-term, real-world reductions in exacerbation frequency, OCS dependency, and exacerbation-related HCRU and costs over 4 years.
DOI: 10.6084/m9.figshare.28418343
title: Demographic and regional mortality trends in patients with asthma in the United States (1999–2020): a CDC WONDER analysis

description: Around 7.7% of Americans have asthma, including 20.2 million adults and 4.6 million children. This study examines asthma mortality trends and disparities across U.S. demographic and geographic groups from 1999 to 2020. A retrospective analysis was conducted using the CDC WONDER database to examine asthma-related deaths in the U.S. from 1999 to 2020. Age-adjusted mortality rates (AAMRs) and crude mortality rates (CMRs) per 100,000 were calculated. Trends and annual percent changes (APCs) were assessed overall and stratified by sex, race, region, and age. From 1999 to 2020, the U.S. recorded 221 161 asthma-related deaths (AAMR: 3.07), mostly in medical facilities. Mortality declined from 1999 to 2018 (APC: −1.53%) but surged from 2018 to 2020 (APC: 28.63%). Females, NH Blacks, and NH American Indians had the highest mortality rates. Older adults (≥65) had the greatest burden, with younger groups showing notable increases post-2018. Rural areas and the West reported slightly higher rates than urban and other regions. Hawaii and the District of Columbia had the highest AAMRs, while Florida and Nevada had the lowest. Asthma-related mortality in the U.S. declined until 2018 but sharply increased from 2018 to 2020, with rises across all demographic groups, regions, and settings. Females, NH Blacks, and older adults consistently had higher mortality rates, while younger age groups showed recent alarming increases. Targeted interventions are urgently needed to address inequities and recent mortality surges.
DOI: 10.6084/m9.figshare.28418343.v1
title: Demographic and regional mortality trends in patients with asthma in the United States (1999–2020): a CDC WONDER analysis

description: Around 7.7% of Americans have asthma, including 20.2 million adults and 4.6 million children. This study examines asthma mortality trends and disparities across U.S. demographic and geographic groups from 1999 to 2020. A retrospective analysis was conducted using the CDC WONDER database to examine asthma-related deaths in the U.S. from 1999 to 2020. Age-adjusted mortality rates (AAMRs) and crude mortality rates (CMRs) per 100,000 were calculated. Trends and annual percent changes (APCs) were assessed overall and stratified by sex, race, region, and age. From 1999 to 2020, the U.S. recorded 221 161 asthma-related deaths (AAMR: 3.07), mostly in medical facilities. Mortality declined from 1999 to 2018 (APC: −1.53%) but surged from 2018 to 2020 (APC: 28.63%). Females, NH Blacks, and NH American Indians had the highest mortality rates. Older adults (≥65) had the greatest burden, with younger groups showing notable increases post-2018. Rural areas and the West reported slightly higher rates than urban and other regions. Hawaii and the District of Columbia had the highest AAMRs, while Florida and Nevada had the lowest. Asthma-related mortality in the U.S. declined until 2018 but sharply increased from 2018 to 2020, with rises across all demographic groups, regions, and settings. Females, NH Blacks, and older adults consistently had higher mortality rates, while younger age groups showed recent alarming increases. Targeted interventions are urgently needed to address inequities and recent mortality surges.